New Targets and Strategies of Medical Treatments in Neurological and Neurodegenerative Disorders

Author(s): Antoni Camins, Carlos Beas-Zarate.

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 12 , 2020

Become EABM
Become Reviewer

Sánchez López E, Lopez Machado AL, Vidal LB, Pizarro RG, Silva AD, Souto EB. Lipid nanoparticles as carriers for the treatment of neurodegeneration associated with Alzheimer’s disease and glaucoma: present and future challenges. Curr Pharm Des 2020; 26(12): 1235-50.
Binvignat O, Olloquequi J. Excitotoxicity as a target against neurodegenerative processes. Curr Pharm Des 2020; 26(12): 1251-62.
Ureña-Guerrero ME, Castañeda-Cabral JL, Rivera-Cervantes MC, et al. Neuroprotective and Neurestorative Effects of Epo and VEGF: Perspectives for New Therapeutic Approaches to Neurological Diseases. Curr Pharm Des 2020; 26(12): 1263-76.
Maldonado C, Vázquez M, Fagiolino P. Potential therapeutic role of carnitine and acetylcarnitine in neurological disorders. Curr Pharm Des 2020; 26(12): 1277-85.
Ettcheto M, Busquets O, Espinosa-Jiménez T, Verdaguer E, Auladell C, Camins A. Chronological review of potential disease modifying therapeutic strategies for Alzheimer’s disease. Curr Pharm Des 2020; 26(12): 1286-99.
Manzine PR, Vatanabe IP, Peron R, et al. Blood-based biomarkers of Alzheimer’s disease: the long and winding road. Curr Pharm Des 2020; 26(12): 1300-15.
Cano A, Espina M, García ML. Recent advances on anti-tumor agents-loaded polymeric and lipid based nano-carriers for the treatment of brain cancer. Curr Pharm Des 2020; 26(12): 1316-30.
Bahadur S, Sachan N, Harwansh RK, Deshmukh R. Nanoparticlized system: promising approach for the management of Alzheimer’s disease through intranasal delivery. Curr Pharm Des 2020; 26(12): 1331-44.
Casadesus G, Servizi S, Corrigan R. The Importance of understanding amylin signaling mechanisms for therapeutic development in the treatment of Alzheimer’s disease. Curr Pharm Des 2020; 26(12): 1345-55.
Auzmendi J, Puchulu MB, Garcia Rodriguez JC, Balaszczuk AM, Lazarowski A, Merelli A. EPO and EPO-Receptor system as potential actionable mechanism to protection of brain and heart in refractory epilepsy and SUDEP. Curr Pharm Des 2020; 26(12): 1356-64.
Jara-Moreno D, Riveros A, Barriga A, Kogan MJ, Delporte C. Inhibition of β-amyloid aggregation of Ugni molinae extracts. Curr Pharm Des 2020; 26(12): 1365-76.
Montiel T, Montes-Ortega LA, Flores-Yáñez S, Massieu L. Treatment with the ketone body D-β-hydroxybutyrate attenuates autophagy activated by NMDA and reduces excitotoxic neuronal damage in the rat striatum in vivo. Curr Pharm Des 2020; 26(12): 1377-87.
Vega-García A, Rocha L, Guevara-Guzmán R, Guerra-Araiza C, et al. Magnolia officinalis Reduces inflammation and damage induced by recurrent status epilepticus in immature rats. Curr Pharm Des 2020; 26(12): 1388-401.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [1233 - 1234]
Pages: 2
DOI: 10.2174/138161282612200506115405

Article Metrics

PDF: 12